To The Moon

Warren Buffett said he would donate about $1.2 billion in Berkshire Hathaway stock to four family foundations, saying he is confident in the ability of his three children to give away his enormous fortune after his death.Buffett, 94 years old, amplified on a message he sent last year when he revealed that his three children, Howard, Susan, and Peter Buffett, would be responsible for giving away his wealth, which consists almost entirely of about $148 billion in Berkshire stock."The children have now more than justified our hopes and, upon my death, will have full responsibility for gradually distributing all of my Berkshire holdings. These now account for 99 1/2 % of my wealth," Buffett wrote to Berkshire Hathaway shareholders, according to a press release Monday.Buffett also elaborated on a decision he revealed a year ago, that the donation decisions after his death need to be unanimous among his three children. He noted that wealthy friends have questioned him about that requirement.

$Alphabet$ 's Google is developing artificial intelligence technology that takes over a web browser to complete tasks such as research and shopping, The Information reported on Saturday.Google is set to demonstrate the product code-named Project Jarvis as soon as December with the release of its next flagship Gemini large language model, the report added, citing people with direct knowledge of the product.Microsoft MSFT.O backed OpenAI also wants its models to conduct research by browsing the we

MIRA Pharmaceuticals Inc stock is trading higher on Thursday, with a strong session volume of 47.90 million, according to data from Benzinga Pro.The company announced new insights from additional recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2.Ketamir-2 is MIRA’s drug candidate being investigated as a potential treatment forneurological and neuropsychiatric disorders.The new preclinical study results announced are the latest in a string of research developments progressing MIRA’s goal of submitting an Investigational New Drug Application to the FDA for Ketamir-2 later this year.The latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor of glutamate, the primary excitatory neurotransmitter in the human brain, specifically interacting at the PCP-binding site of the NMDA complex.Ketamir-2 has a 30-50-fold lower affinity to the PCP site than ketamine.These fi

Nike stock, to use a sports metaphor, is getting blown out. But with a brand as good as the swoosh, you can always count on a comeback.Nike will eventually take advantage of its enormous marketing war chest and upcoming events -- including the Paris Olympics opening Friday -- to right its mistakes. For now, investors can pick up the stock at its cheapest price in more than a decade.Barron's was among those caught off guard by Nike's woes. We recommended the stock to readers earlier this summer. Still, given Nike's enormous strengths -- including a globally recognized brand, marketing prowess, and enormous ad budget -- we think we were early, not wrong.While Nike has since re-established many wholesale relationships, it compounded the error by letting newcomers like Hoka and On gain a foothold in the core running shoe market. Shares of Hoka maker Deckers Outdoor are up 26% this year. Those of On Holding AG have gained 46%.

(Reuters) - $GitLab(GTLB)$, a U.S. provider of cloud-based software development tools whose investors include Google parent Alphabet, is exploring a sale after attracting acquisition interest, accordi

For investors looking at the EV sector, Tesla has been a staple stock to hold. But has the tide turned for TSLA stock moving forward?